CKD-516
Modify Date: 2025-08-30 12:59:27
CKD-516 structure
|
Common Name | CKD-516 | ||
|---|---|---|---|---|
| CAS Number | 1240321-53-2 | Molecular Weight | 573.06400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H29ClN6O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CKD-516Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine prodrug of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2]. |
| Name | (2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine prodrug of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2]. |
|---|---|
| Related Catalog | |
| Target |
β-tubulin polymerization[1] |
| In Vivo | Valecobulin (5 mg/kg; intraperitoneal injection; administered on days 2, 6, 10, and 14; male BALB/C nu/nu mice) treatment shows markedly antitumor efficacy in various human tumor xenograft models[1]. Animal Model: Male BALB/C nu/nu mice (5-6 weeks of age) with HCT-116 or HCT-15 cells[1] Dosage: 5 mg/kg Administration: Intraperitoneal injection; administered on days 2, 6, 10, and 14 Result: Had shown marked antitumor efficacy in various human tumor xenograft models. |
| References |
| Molecular Formula | C26H29ClN6O5S |
|---|---|
| Molecular Weight | 573.06400 |
| Exact Mass | 572.16100 |
| PSA | 175.21000 |
| LogP | 5.72120 |
| CKD-516 |
| UNII-2J9QE0TM5I |
| (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide hydrochloride |